Connect with us

Medical Devices

CloudCath Announces Collaboration with American Renal Associates in Pre-Market Clinical Study for Peritoneal Dialysis Patients



Innovative Remote Monitoring Platform Will Be Tested for In-Home Use

SAN FRANCISCO–(BUSINESS WIRE)– CloudCath, developer of a remote monitoring and predictive analytics platform for catheter-based treatments, today announced a collaboration with American Renal Associates (ARA), a leading provider of outpatient dialysis services. In a U.S.-based, pre-market clinical study, ARA will evaluate the use of CloudCath’s System by peritoneal dialysis (PD) patients. PD is a method of dialysis allowing patients to administer their own dialysis treatments in their home.

Operating 239 dialysis clinics in 27 states and Washington D.C., ARA partners with approximately 400 nephrologists to advocate for better care and better outcomes for more than 17,000 patients with end stage renal disease (ESRD).

“We are pleased to partner with CloudCath through the clinical evaluation of an innovative technology that can dramatically shift the way patients use peritoneal dialysis,” said Ann Mooney, Vice President of Clinical Research at American Renal Associates. “We recognize the heightened sense of urgency for both patients and medical professionals to feel more confident in the self-administration of home-based dialysis care through remote monitoring. Peritoneal dialysis has demonstrated significant health benefits and increased quality of life for patients. We believe CloudCath’s remote monitoring device can greatly benefit the 60,000 U.S. patients that currently utilize PD.”

CloudCath’s remote monitoring and predictive analytics platform is initially being applied to improve care for PD and ESRD patients. By analyzing the drained dialysate captured from home-based PD cyclers, the CloudCath System will be able to gather comprehensive biological data to provide real time insights into a patient’s health.

“The clinical partnership that we have forged with ARA, one of the largest dialysis services providers in the United States, is testament to the significance of our technology,” said Aly ElBadry, CEO and Co-Founder of CloudCath. “Access to ARA’s wealth of patient advocacy expertise and vast network will be especially valuable as the CloudCath System advances toward commercialization. We are honored to partner with ARA in a shared aspiration to bring better treatment choices to PD patients and to champion the shift toward more convenient, home-based care.”

In addition to substantial clinical, systemic, and economic value creation, home-based PD is broadly recognized as a treatment that aligns well with patient aspirations for greater convenience, including the ability to work full-time or part-time and to have a career, to start a family, own a home, and retire securely. The COVID-19 pandemic has further heightened demand for remote dialysis modalities.

Designed to advance PD care with real-time, remote monitoring, the CloudCath System can directly address the challenges associated with PD and facilitate a shift toward life-saving and convenient, home-based treatment.

About American Renal Associates

American Renal Associates is a leading provider of outpatient dialysis services in the United States. ARA operates 239 dialysis clinics in 27 States and the District of Columbia serving more than 17,000 patients with end stage renal disease. For more information about American Renal Associates, visit

About CloudCath

Incepted in San Francisco in 2017, CloudCath has developed a cloud-connected, remote monitoring platform for catheter-based treatments. The first application of the technology has been designed to improve care for PD patients. Easy-to-use and easy to set up, the CloudCath System enables dialysis providers to monitor their patients’ state and progression in real time, promoting earlier intervention and fewer hospitalizations. To support future commercialization and product development, the Company is generating evidence through a U.S.-based pre-market clinical study. For more information about CloudCath, visit

Coinsmart. Beste Bitcoin-Börse in Europa

Medical Devices

Sciton Celebrates the Newest Innovation in United Kingdom: Sciton’s mJOULE



Exceptional Outcomes Now Available Overseas

LONDON, June 18, 2021 /PRNewswire/ — Sciton® Inc., a leading manufacturer of medical and aesthetic lasers and light source technologies based in Palo Alto, California, announces the launch of its latest platform, mJOULE, in the United Kingdom. This revolutionary system features some of the biggest updates in the history of pulsed light based technology, including its newest fractional treatment, MOXI, and the award-winning BBL HERO treatment.

Sciton® Inc., announces the launch of its latest platform, mJOULE, which includes MOXI and BBL HERO in the UK.

“At Sciton, we work hand in hand with our clinician partners to drive visionary innovation that is founded on science and uncompromised quality,” shares Aaron Burton, Sciton CEO. “We are proud to be leading the industry with new product innovation and enhancements that benefit practices and patients alike.”

mJOULE is a dual wavelength platform that features BBL HERO and MOXI technologies, created in response to a changing market which desires less time consuming treatments, yet equally strong outcomes. Recently honored by NewBeauty as a 2020 ‘Innovation Award Winner,’ BBL HERO (High Energy Rapid Output) is the fastest, most powerful IPL in the industry, and empowers practitioners to treat the entire body with four times the speed, three times the peak intensity, allowing for a highly customizable protocol. The treatment results in smoother, clearer, younger and healthier looking skin in just one to two sessions.

“Sciton is dedicated to worldwide support and growth. We continue to demonstrate our commitment to developing high quality devices and marketing efforts for our physician and medspa partners worldwide.” says Lacee J. Naik, Vice President of Marketing and Public Relations.

The second technology available on the mJOULE platform is Sciton’s newest fractional laser, MOXI. MOXI is one of the most inclusive laser treatments available, and is safely suitable for those higher on the Fitzpatrick scale. This non-ablative laser addresses sun damage and aging, takes under 20 minutes and boasts little to no downtime, allowing it to fit comfortably into even the busiest of schedules and can be performed any time of the year.

“The U.K. is an important market for Sciton’s global growth strategy,” says David Percival, Vice-President and General Manager for Sciton International. “We see a tremendous opportunity to introduce both these novel technologies into the growing aesthetic market in the U.K. We have a strong reputation for delivering an outstanding customer experience and look forward to expanding our Sciton family of customers.”

Sciton will celebrate this monumental international launch with a premier event in London on June 24th, 2021, where staff, partners, and leadership will gather to recognize this milestone and officially welcome their ground-breaking technologies to the dynamic UK market.

Sciton, Inc., located in Palo Alto, California, is an employee-owned medical device company established in 1997 by co-founders Jim Hobart, Ph.D., and Dan Negus, Ph.D. Sciton is committed to providing best-in-class laser and light solutions for medical professionals who want superior durability, performance and value. Sciton offers aesthetic and medical devices for women’s health, fractional and full-coverage skin resurfacing and skin revitalization, phototherapy, vascular and pigmentation lesions, scar reduction, acne, body contouring, and hair reduction. Sciton operates on a worldwide basis with direct sales teams in the United States, Canada, Australia, United Kingdom, Ireland, Japan and distributor partners in more than 45 countries. For more information, and a complete listing of Sciton systems, visit

Facebook: @ScitonInc
Instagram: @Sciton_Inc
LinkedIn: @ScitonInc

Cision View original content to download multimedia:

SOURCE Sciton, Inc.

Coinsmart. Beste Bitcoin-Börse in Europa

Continue Reading

Medical Devices

Avanos Medical, Inc. to Present at the 2021 Raymond James Human Health Innovation Conference



ALPHARETTA, Ga., June 18, 2021 /PRNewswire/ — Avanos Medical, Inc. (NYSE: AVNS) today announced that Joe Woody, chief executive officer, will present and participate in an analyst-led fireside chat at the Virtual 2021 Raymond James Human Health Innovation Conference Tues., June 22 at approximately 10:40 a.m., ET.

A live webcast of conference presentation will be available on the Investors section of the Avanos Medical website and will be archived on that site.

About Avanos Medical:
Avanos Medical (NYSE: AVNS) is a medical technology company focused on delivering clinically superior breakthrough medical device solutions to improve patients’ quality of life. Headquartered in Alpharetta, Georgia, Avanos is committed to addressing some of today’s most important healthcare needs, such as reducing the use of opioids while helping patients move from surgery to recovery. Avanos develops, manufactures and markets its recognized brands in more than 90 countries. For more information, visit and follow Avanos Medical on Twitter (@AvanosMedical), LinkedIn and Facebook.

Cision View original content to download multimedia:

SOURCE Avanos Medical

Company Codes: NYSE:AVNS

Coinsmart. Beste Bitcoin-Börse in Europa

Continue Reading

Medical Devices

Sequana Medical to Host a Key Opinion Leader Webinar on “The Impact of Liver Ascites on Patients and Healthcare Systems and the potential of alfapump® therapy in NASH-related ascites”



Live webinarwith Dr.Vargas and Dr. Knuttinenon15 July 2021at 4 pm CET / 10 am ET

GHENT, Belgium, June 17, 2021 (GLOBE NEWSWIRE) — Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces that it will host a Key Opinion Leader (KOL) call on July 15th, 2021 from 4 pm CET / 10 am ET to 5 pm CET / 11 am ET. The KOL call will discuss the impact of recurrent and refractory liver ascites on patients and healthcare systems and the potential of alfapump therapy in NASH-related ascites.

The webinar will feature a testimonial from a patient living with refractory ascites and treated with alfapump, followed by a presentation by KOLs Hugo E. Vargas, M.D. and Grace Knuttinen, M.D., Ph.D., both of Mayo Clinic, who will discuss the impact of ascites on the patients’ quality of life and the limitations of current treatment options. They will also share their experience with the alfapump implantation and discuss its potential in the treatment paradigm for these patients. A Q&A session with the KOLs and Sequana Medical management will follow the formal presentations.

Ascites is the most common reason for hospitalisation of patients with advanced liver disease and is forecast to grow dramatically driven by NASH-related cirrhosis. Sequana Medical’s alfapump has been granted FDA breakthrough device designation for the treatment of recurrent or refractory ascites due to liver cirrhosis.

The alfapump is a fully implantable pump system that moves ascites from the peritoneal cavity into the bladder, where it is passed naturally from the body through urination. The alfapump is approved in Europe and POSEIDON, the North American pivotal study to support regulatory approval in the US and Canada is underway. Positive interim data from the POSEIDON study were reported in November 2020 with further interim data expected in Q2 2021 and primary endpoint data in Q2 2022.

The webinar will be webcasted live at To get access to the webinar a registration in advance is required. The presentation and a replay of the webinar will be available on the website of Sequana Medical shortly after the event.

For more information, please contact:

Sequana Medical
Lies Vanneste
Director Investor Relations
Tel: +32 498 05 35 79

LifeSci Advisors
Guillaume van Renterghem
Tel: +41 76 735 01 31

About Dr. Vargas

Hugo E. Vargas, M.D. is a Mayo Clinic Consultant in the Department of Gastroenterology and Hepatology and the Mayo Clinic Transplantation Center. His current clinical and research interests include management of cirrhosis complications, acute chronic liver disease and alcohol related liver disease. Dr. Vargas is the Medical Director for the Office of Clinical Research – Arizona and a Professor of Medicine in the Mayo Clinic Alix School of Medicine and is the Chair of the Clinical Research Subcommittee, and the Vice Chair of the Arizona Research Operations Management Team. Dr. Vargas received his M.D. from Hahnemann University Graduate School of Medicine, has authored or coauthored more than 125 peer-reviewed articles and is a Fellow of the AASLD, AGA, ACG, ASGE and ACP.

About Dr. Knuttinen

Grace Knuttinen, M.D., Ph.D. is a Mayo Clinic Consultant and Professor in the Department of Radiology. She is an interventional radiologist with Mayo Clinic in Phoenix, with clinical and research interests in hepatobiliary disease, the management of post liver transplant complications, and vascular disease. Dr. Knuttinen has more than 20 years’ experience in interventional radiology and is a member of the Leadership Academy of the Society of Interventional Radiology and an Invited ABR Board Examiner for International Radiology at the American Board of Radiology. She is the Director for the Mayo Alix School of Medicine Dual Degree program, and the Director for the Barretts ASU- Mayo Alix School of Medicine Premedical Scholars program. Dr. Knuttinen received her M.D. and Ph.D. from Northwestern University, has coauthored over 95 peer-reviewed articles and written 13 book chapters. She is a Fellow of the Society of Interventional Radiology (SIR) and is the chair of a national SIR committee and currently the principal investigator of an ongoing national prospective funded clinical trial.

About Sequana Medical

Sequana Medical is a commercial stage medical device company utilizing its proprietary alfapump® and DSR® (Direct Sodium Removal) technologies to develop innovative treatments for fluid overload in liver disease, malignant ascites and heart failure where diuretics are no longer effective. Fluid overload is a frequent complication of many large diseases including advanced liver disease driven by NASH (non-alcoholic steatohepatitis)-related cirrhosis and heart failure, with diuretic resistance being widespread. The U.S. market for the alfapump resulting from NASH-related cirrhosis is forecast to exceed €3 billion annually within the next 10-20 years. The heart failure market for DSR and the alfapump DSR® is estimated to be over €5 billion annually in the U.S. and EU5 by 2026.

The alfapump is a unique, fully implanted wireless device that automatically pumps fluid from the abdominal cavity into the bladder, where it is naturally eliminated through urination. DSR is Sequana Medical’s proprietary approach to managing sodium and fluid overload through use of a sodium-free infusate administered into the abdominal cavity.

In the U.S., the Company’s key growth market, the alfapump has been granted breakthrough device designation by the FDA for recurrent or refractory ascites due to liver cirrhosis. Interim data from the ongoing North American pivotal study (POSEIDON) showed positive outcomes against all primary endpoints of the study. This study is intended to support a future marketing application of the alfapump in the U.S. and Canada. In Europe, the alfapump is CE-marked for the management of refractory ascites due to liver cirrhosis and malignant ascites and is included in key clinical practice guidelines. Over 850 alfapump systems have been implanted to date.

Sequana Medical has combined its proven alfapump and proprietary DSR therapy, and is developing the alfapump DSR, a breakthrough approach to fluid overload due to heart failure. RED DESERT, the repeated dose alfapump DSR study in diuretic-resistant heart failure patients has demonstrated that repeated DSR therapy is able to both manage the fluid and sodium balance of these patients as well as restore their diuretic response and improve their cardio-renal status. The SAHARA DESERT study of alfapump DSR in decompensated heart failure patients is ongoing.

Sequana Medical is headquartered in Ghent, Belgium. For further information, please visit

Important Regulatory Disclaimers

The alfapump® system is not currently approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. For more information regarding the POSEIDON clinical study see The DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. The DSR® therapy is not currently approved for clinical research in the United States or Canada. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Note:alfapump® is a registered trademark. DSR® and alfapump DSR® are registered trademarks in the Benelux.

Forward-looking statements

This press release may contain predictions, estimates or other information that might be considered forward-looking statements. Such forward-looking statements are not guarantees of future performance. These forward-looking statements represent the current judgment of Sequana Medical on what the future holds, and are subject to risks and uncertainties that could cause actual results to differ materially. Sequana Medical expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release, except if specifically required to do so by law or regulation. You should not place undue reliance on forward-looking statements, which reflect the opinions of Sequana Medical only as of the date of this press release.

Primary Logo

Coinsmart. Beste Bitcoin-Börse in Europa

Continue Reading

Medical Devices

Avisa Diagnostics to Participate in Renmark’s Virtual Non-Deal Roadshow Series on June 17, 2021



SANTA FE, N.M., June 17, 2021 (GLOBE NEWSWIRE) — Avisa Diagnostics Inc. (CSE: AVBT) (Avisa), a clinical-stage medical device company developing an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of bacterial load in post-COVID-19 long haulers and for ventilator-associated pneumonia, announced today that the Company will participate in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series on June 17, 2021 at 12:00 PM ET.

Avisa Diagnostics’ President and CEO, David S. Joseph, will give a company presentation, followed by a live Q&A session. Investors interested in participating in this event will need to register using the link below. Registration for the live event may be limited, but access to a replay after the live event will be available on the Company’s website ( in the Investors section.


To ensure smooth connectivity, please access this link using the latest version of Google Chrome.

About Renmark Financial Communications Inc.

Founded in 1999, Renmark Financial Communications Inc. is North America’s leading retail investor relations firm. Employing a strategic and comprehensive mix of exposure tactics; Renmark hosts Virtual Non-Deal Roadshows as well as in-person corporate presentations and maintains daily communications with thousands of brokers and money managers across Canada and the United States. Renmark empowers its publicly-traded clientele to maximize their visibility within the financial community and strengthen their investor audience. For more information about Renmark and its events, please contact Scott Logan at, +1 (416) 644-2020 or +1 (514) 939-3989.

About Avisa Diagnostics Inc.

Avisa (CSE-AVBT) is a clinical-stage medical device company developing the Avisa BreathTest™, a novel drug/device biomarker technology platform that enables the ultra-rapid detection of virulent bacterial pathogens, detecting and monitoring bacterial load after the patient inhales or ingests its proprietary drug substrates. The Company has established clinical proof-of-concept through trials in cystic fibrosis, tuberculosis and community-acquired pneumonia, which demonstrated positive safety and clinical efficacy results. Avisa is planning pivotal trials in Post-COVID-19 bronchiectasis and ventilator-associated pneumonia and plans to submit Investigational Device Exemption applications to the U.S. FDA for these trials next year. For further information, visit and follow us on LinkedIn and Twitter.

Avisa Diagnostics Inc.
David S. Joseph
President and Chief Executive Officer
Phone: +1 610 947 0360

Investors and Media Contacts
MC Services AG
Laurie Doyle, Raimund Gabriel
Europe: +49 89-210 2280
U.S.: +1-339-832-0752

Forward-looking Statements

This press release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities and operating performance. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions and includes, but is not limited to, statements about the business plans and expectations of the Company and expectations for other economic, business, and/or competitive factors. Investors are cautioned that forward- looking information is not based on historical facts but instead reflects the Company’s management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Resulting Issuer. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: (i) changes in general economic, business and political conditions, including changes in the financial markets, changes in applicable laws and regulations both locally and in foreign jurisdictions; (ii) compliance with extensive government regulation and the costs associated with compliance; (iii) the risks and uncertainties associated with foreign markets; and (iv) risks associated with the COVID-19 pandemic. This forward-looking information may be affected by risks and uncertainties in the business of the Resulting Issuer and market conditions. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended and such changes could be material. The Company does not intend, nor assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Primary Logo

Coinsmart. Beste Bitcoin-Börse in Europa

Continue Reading
Energy4 days ago

Extensive Demand from the Personal Care and Cosmetics Industry Coupled with the Booming Construction Industry will Invite Impactful Growth for the Mineral Oil & Mineral Spirit Market: TMR

Esports2 days ago

World of Warcraft 9.1 Release Date: When is it?

Energy2 days ago

Biocides Market worth $13.6 billion by 2026 – Exclusive Report by MarketsandMarkets™

Esports3 days ago

Clash of Clans June 2021 Update patch notes

Blockchain4 days ago

Africa Leading Bitcoin P2P Trading Volume Growth in 2021

Aviation4 days ago

Boeing 727 Set To Be Turned Into Luxury Hotel Experience

Big Data4 days ago

In El Salvador’s bitcoin beach town, digital divide slows uptake

HRTech3 days ago

Pre-Owned Luxury Car dealer Luxury Ride to add 80 Employees across functions to boost growth

Blockchain3 days ago

Former PayPal Employees Launch Cross-Border Payment System

Blockchain4 days ago

Since It Adopted Bitcoin As Legal Tender, The World Is Looking At El Salvador

Gaming5 days ago

Her Story Creator’s Next Game is Immortality, Releases in 2022

Energy2 days ago

XCMG dostarcza ponad 100 sztuk żurawi dostosowanych do regionu geograficznego dla międzynarodowych klientów

Aviation5 days ago

Delta Air Lines Airbus A320 Returns To Minneapolis After Multiple Issues

Blockchain2 days ago

PancakeSwap (CAKE) Price Prediction 2021-2025: Will CAKE Hit $60 by 2021?

Aerospace4 days ago

Delivering economic and societal value

Esports2 days ago

Here are the patch notes for Call of Duty: Warzone’s season 4 update

Gaming3 days ago

Super Smash Bros. Ultimate – Tekken’s Kazuya Mishima is the Next Challenger pack

Gaming5 days ago

Severed Steel is a Bullet Time-Heavy Voxel FPS With a Unique Protagonist

Esports2 days ago

Here are the patch notes for Brawl Stars’ Jurassic Splash update

Aviation4 days ago

Icelandic Carrier PLAY Reveals Stunning Airbus A321neo